BioVascular
BioVascular is a San Diego-based private company founded in 2006 that develops drugs and devices for platelet-mediated cardiovascular diseases; its website is currently parked and no active operations, products, or management are visible in available sources.
- Company typePrivate
- Founded2006
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
BioVascular firmographics
Firmographics- Name
- BioVascular
- Website
- https://biovascularinc.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BioVascular is a San Diego-based private company founded in 2006 that develops drugs and devices for platelet-mediated cardiovascular diseases; its website is currently parked and no active operations, products, or management are visible in available sources.
- Ownership category
- akta.pro rank
BioVascular industry classification
Industry- Product category
- Cardiovascular Therapeutics
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industry
- Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where BioVascular is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
BioVascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
BioVascular product offering
Product offeringCore offering
BioVascular develops and commercializes pharmaceutical drugs and medical devices aimed at controlling platelet-mediated cardiovascular diseases. The company operates as a small, privately-held biopharmaceutical venture based in San Diego, focused on therapeutic interventions targeting platelet function in cardiovascular pathology.
Differentiator
Problem solved
Functional benefit
Companies that use BioVascular
Customer profileIdeal customer profiles2 records
BioVascular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
BioVascular competitors and assessment
Company assessmentBroad incumbents
- Daiichi Sankyo: Developer of Lixiana/Savaysa (edoxaban) and partner on prasugrel; a major antithrombotic franchise player with direct therapeutic overlap.
- Abbott Vascular: Cardiovascular device arm of Abbott competing in coronary intervention, embolic protection, and structural heart; relevant peer for BioVascular's device ambitions.
- AstraZeneca: Markets Brilinta (ticagrelor), one of the leading antiplatelet agents for acute coronary syndrome; directly comparable therapeutic and indication overlap with BioVascular.
- Medtronic: Largest cardiovascular device franchise, with products spanning coronary stents, antithrombotic-related interventional tools, and structural heart - overlapping with the device half of BioVascular's offering.
- Bristol-Myers Squibb: Major incumbent in cardiovascular therapeutics via Eliquis (apixaban) and historically Plavix (clopidogrel); competes directly in platelet/coagulation-mediated cardiovascular disease treated by BioVascular's pipeline.
- Boston Scientific: Major interventional cardiovascular device company with coronary, structural heart, and peripheral vascular portfolios; comparable on the device side of BioVascular's charter.
- Eli Lilly: Co-marketed Effient (prasugrel) with Daiichi Sankyo, an antiplatelet therapy for ACS patients undergoing PCI; comparable branded cardiovascular franchise.
- Johnson & Johnson: Markets Xarelto (rivaroxaban) jointly with Bayer across thrombosis and cardiovascular indications; broad incumbent in platelet/coagulation-mediated disease.
Direct peers
- Portola Pharmaceuticals: Specialty biopharmaceutical company focused on thrombosis and other hematologic/cardiovascular disorders; its lead asset Andexxa targeted factor Xa inhibitor-related bleeding, directly comparable to BioVascular's platelet-mediated cardiovascular focus.
- Penumbra: Specialized device company in thrombectomy and embolic protection/stroke intervention; product set directly comparable to the 'devices for platelet-mediated cardiovascular disease' segment of BioVascular's charter.
Market position
Customer concentration
BioVascular social profiles
Digital presenceBioVascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioVascular leadership team
Management profileNumber of profiles
BioVascular funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioVascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioVascular
What does BioVascular do?
BioVascular develops and commercializes pharmaceutical drugs and medical devices aimed at controlling platelet-mediated cardiovascular diseases. The company operates as a small, privately-held biopharmaceutical venture based in San Diego, focused on therapeutic interventions targeting platelet function in cardiovascular pathology.
Is BioVascular a public or private company?
BioVascular is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioVascular founded?
BioVascular was founded in 2006. It employs 1 to 10 people.
Where is BioVascular based?
BioVascular is headquartered in San Diego, United States, in the North America region.
Who are BioVascular's main competitors?
Broad incumbents on record are Daiichi Sankyo, Abbott Vascular, AstraZeneca, Medtronic, Bristol-Myers Squibb, Boston Scientific, Eli Lilly and Johnson & Johnson. Direct peers are Portola Pharmaceuticals and Penumbra.
Does BioVascular have an API?
No public API is recorded for BioVascular.
What industry is BioVascular in?
BioVascular's product category is Cardiovascular Therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 3254 and its SIC code is 2834.